Dyne Therapeutics (DYN) Operating Leases (2021 - 2026)

Dyne Therapeutics (DYN) has 6 years of Operating Leases data on file, last reported at $14.3 million in Q1 2026.

• On a quarterly basis, Operating Leases fell 21.67% year-over-year to $14.3 million in Q1 2026; TTM through Mar 2026 was $14.3 million, a 21.67% decrease from a year earlier, with the FY2025 full-year figure at $15.3 million, down 20.14% from the prior year.
• Operating Leases for Q1 2026 stood at $14.3 million, down from $15.3 million in the prior quarter.
• Over the last five years, Operating Leases for DYN reached as high as $28.1 million in Q1 2022 and fell as low as $14.3 million in Q1 2026.
• Historically, Operating Leases has averaged $21.6 million across 5 years, with a median of $21.9 million in 2024.
• Across the five-year window, Operating Leases surged 6685.36% in 2022 and slipped 21.67% in 2026, its largest moves.
• Year by year, Operating Leases stood at $25.9 million in 2022, then retreated by 12.28% to $22.7 million in 2023, then decreased by 15.67% to $19.1 million in 2024, then dropped by 20.14% to $15.3 million in 2025, then fell by 6.62% to $14.3 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $14.3 million in Q1 2026, $15.3 million in Q4 2025, and $16.3 million in Q3 2025.